Home
Company
Product
Regulation
China
Data
Exhibition
Interview
中文版
Home
Company
Product
Regulation
China
Data
Exhibition
Interview
中文版
Search

PMI Launches IQOS ILUMA in Macedonia

BusinessPMI by 2FIRSTS.ai
Nov.21.2023
PMI Launches IQOS ILUMA in Macedonia
Philip Morris International (PMI) has launched its new smoke-free device IQOS ILUMA in the Macedonia market.

According to a report by crnobelo on November 20, Philip Morris International (PMI) has launched its new smoke-free device, IQOS ILUMA, in the Macedonian market.

 

IQOS ILUMA will be introducing three different models in Macedonia: IQOS ILUMA PRIME, IQOS ILUMA, and IQOS ILUMA ONE. This series of products falls under the category of Heat-Not-Burn (HNB) devices, designed to cater to the diverse needs of adult users.

 

References:
[1] Новите IQOS ILUMA лансирани во Македонија: За иднина без чад од тутун
Also Read:
[1] Brazilian Tobacco Industry Supports Proposed E-cigarette Regulation Law
[2] Czech Republic Implements Ban on Flavored Tobacco Products
#Europe#Products#PMI#IQOS ILUMA#Heated tobacco products#Macedonia

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

China Tobacco Regulation Shift：Policy Updates and Market Impact
China Tobacco Regulation Shift：Policy Updates and Market Impact
South Korea’s appeal court again sides with KT&G, Philip Morris Korea and BAT Korea in $36.24 million case
South Korea’s appeal court again sides with KT&G, Philip Morris Korea and BAT Korea in $36.24 million case
South Korea’s National Health Insurance Service (NHIS) has again lost on appeal in its damages lawsuit against KT&G, Philip Morris Korea and BAT Korea, seeking ₩53.3 billion (about $36.244 million).
Jan.15 by 2FIRSTS.ai
Exclusive｜Suspected China Tobacco Nicotine Oral Film Product Surfaces on Social Media
Exclusive｜Suspected China Tobacco Nicotine Oral Film Product Surfaces on Social Media
China Tobacco Jiangsu IC appears to have developed a nicotine oral film product under the "Nanjing" brand, according to images circulating on Chinese social media. If confirmed, this could potentially mark China Tobacco's first oral nicotine product targeting the domestic market. The product's authenticity has not been officially verified, and no nicotine pouch products have been approved for sale in China.
Special Report
Feb.09
Consultation opens for Tasmania’s Public Health Amendment Bill 2026
Consultation opens for Tasmania’s Public Health Amendment Bill 2026
Consultation opened on February 6, 2026 for the Public Health Amendment (Prohibited Tobacco and Other Products) Bill 2026. The Bill intends to address illicit trade in tobacco, nicotine pouches and e-cigarettes, which has increased significantly across Tasmania in recent years. It proposes changes to the Public Health Act 1997 to further protect the health of Tasmanians by reducing the sale and supply of illicit tobacco, vaping and other products, and to strengthen existing tobacco control laws.
Feb.06 by 2FIRSTS.ai
Product | GEEKBAR Expands High-Puff Lineup; CLR 50K and Clio X Highlight Displays and Transparent E-Liquid Tanks
Product | GEEKBAR Expands High-Puff Lineup; CLR 50K and Clio X Highlight Displays and Transparent E-Liquid Tanks
GEEKBAR has added two new vaping products on its official website. Both feature transparent e-liquid tanks and are rated for up to 50,000 puffs. The CLR 50K is equipped with a 17 ml e-liquid capacity, is labeled at 5% nicotine (50 mg/ml), and offers Normal and Pulse modes, while the Clio X carries a 16 ml capacity, a dual-screen display, and three output modes.
Feb.28 by 2FIRSTS.ai
Andy Tan Named 2026 SRNT Fellow for Contributions to Nicotine Research
Andy Tan Named 2026 SRNT Fellow for Contributions to Nicotine Research
Andy Tan, Ph.D., has been named a 2026 Fellow of the Society for Research on Nicotine and Tobacco (SRNT), an international professional association dedicated to advancing nicotine and tobacco research. Fellows are selected for outstanding research contributions as well as leadership, mentoring, and policy engagement within the field.
Feb.23
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
Related Topics
HEADLINE News Product
Related Read
South Korea’s appeal court again sides with KT&G, Philip Morris Korea and BAT Korea in $36.24 million case
South Korea’s appeal court again sides with KT&G, Philip Morris Korea and BAT Korea in $36.24 million case
2FIRSTS.ai
Exclusive｜Suspected China Tobacco Nicotine Oral Film Product Surfaces on Social Media
Exclusive｜Suspected China Tobacco Nicotine Oral Film Product Surfaces on Social Media
Consultation opens for Tasmania’s Public Health Amendment Bill 2026
Consultation opens for Tasmania’s Public Health Amendment Bill 2026
2FIRSTS.ai
Product | GEEKBAR Expands High-Puff Lineup; CLR 50K and Clio X Highlight Displays and Transparent E-Liquid Tanks
Product | GEEKBAR Expands High-Puff Lineup; CLR 50K and Clio X Highlight Displays and Transparent E-Liquid Tanks
2FIRSTS.ai
Andy Tan Named 2026 SRNT Fellow for Contributions to Nicotine Research
Andy Tan Named 2026 SRNT Fellow for Contributions to Nicotine Research
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
FOLLOW US ON SOCIAL MEDIA
Contact: info@2firsts.com
Stay up to date.
Submit your email to receive weekly newsletter on the most relevant news of the e-cigarette industry.
© 2026 2FIRSTS. All Right Reserved.
2FIRSTS is only accessible to industry practitioners, researchers, media and other professionals. Access by minors is prohibited.
This website provides services to users outside the Chinese mainland.
English
English
中文